Table 3. Dose adjustments.
| Day 1 and 15 lab values | Irinotecan (%) | Oxaliplatin (%) | Uft (%) | |
|---|---|---|---|---|
| Bilirubin a | ALP a | |||
| <1.5 × n | <5 × n | 100 | 100 | 100 |
| 1.5–3 × n | >5 × n | 50 | 100 | Omit |
| >3 × n | — | Omit | Omit | Omit |
| Cockcroft (GFR; ml min−1) b | ||||
| >50 | 100 | 100 | 100 | |
| 30–50 | 100 | 50 | 100 | |
| <30 | 50 | Omit | 1 cap reductionc | |
a
Deteriorating liver function during treatment could indicate progressive disease or biliary obstruction and was investigated by ultrasound examination.
b
Deteriorating renal function during treatment could indicate progressive pelvic disease and ureteric obstruction and was investigated by ultrasound examination.
c
UFT is available in 100 mg capsules. All calculated doses were rounded to the nearest no. of capsules.